NasdaqGS:OLMABiotechs
Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?
If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way.
The stock recently closed at US$25.72, with returns of 1.9% over 7 days, 2.9% over 30 days, 1.7% year to date and 320.9% over the past year, while the 3 year return sits at 465.3% and the 5 year return at a 45.7% decline.
Recent attention on Olema has centered on its position in the pharmaceuticals and biotech space...